XML 57 R48.htm IDEA: XBRL DOCUMENT
v3.10.0.1

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 08, 2017 | Jul. 06, 2017 | Sep. 01, 2014 | Jun. 23, 2018 | Apr. 18, 2018 | May 31, 2017 | Oct. 25, 2016 | Jun. 30, 2016 | May 31, 2016 | Dec. 31, 2015 | Jan. 31, 2015 | Sep. 30, 2014 | Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2017 | Jun. 21, 2016
Operating lease periodic payment |  |  |  |  |  |  |  |  |  |  | $ 709 |  |  |  |  |  |  |  |  |  |
Frequency of periodic payment |  |  |  |  |  |  |  |  |  |  | Monthly |  |  |  |  |  |  |  |  |  |
Operating lease rental expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,147 |  | $ 2,126 |  | $ 4,251 | $ 8,502 | $ 4,960 |  |
Operating lease expiration date |  |  |  |  |  |  |  |  |  |  | May 31, 2017 |  |  |  |  |  |  |  |  |  |
Lease agreement description |  |  |  |  |  |  |  |  |  |  | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.</font></p> |  |  |  |  |  |  | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The Company has negotiated and entered into a two-year amendment to that lease that commenced as of June 1, 2017 through May 31, 2019. The monthly rate from June 1, 2017 through May 31, 2018 is $709 per month and increases to $730 per month from June 1, 2018 through May 31, 2019.</font></p> |  |  |
Stock Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business acquisition, description |  |  |  | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">The purchase price payable in cash is €700,000. Closing of the acquisition is subject to satisfactory completion of due diligence, delivery of audited and interim financial statements of Cosmofarm subject to being audited by PCAOB auditors, no material adverse change in the business or financial condition of Cosmofarm, all necessary consents and approvals to complete the acquisition have been obtained and other customary closing conditions. As of June 30 2017, Cosmofarm is undergoing an audit of the company’s financial statements for the last two years by a PCAOB audit firm, the SPA has not closed and Cosmos has not paid the €700,000.</font></p> |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and contingencies description | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">On August 8, 2017, the Company entered into an agreement with a third-party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.</font></p> |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lease agreement description | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">In connection with the Company’s November 16, 2017 Note offering, the Agent received a cash commission of $240,000, equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in the offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors, or 53,600 shares); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. The Warrants are exercisable six (6) months after the date of issuance, or May 16, 2018.</font></p> |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SkyPharm [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  | $ 4,802 |  |  | $ 1,250 |  |  |  |  |  | $ 4,802 |  |  |  |  |  |  |  |  |
Frequency of periodic payment |  |  | Monthly |  |  | Monthly |  |  |  |  |  | Monthly |  |  |  |  |  |  |  |  |
Operating lease rental expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 32,684 |  | 25,198 | $ 65,367 | 50,397 |  |  |  |
Term of operating lease |  |  | 6 years |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |
Advisory agreement, description |  |  |  |  | <p style="margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term.</font></p> |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SkyPharm [Member] | Additional space [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  |  | $ 2,021 | $ 886 |  |  |  |  |  |  |  |  |  |  |  |
Frequency of periodic payment |  |  |  |  |  |  |  | Monthly | Monthly |  |  |  |  |  |  |  |  |  |  |  |
SkyPharm [Member] | First Floor [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  |  |  |  | $ 886 |  |  |  |  |  |  |  |  |  |  |
Frequency of periodic payment |  |  |  |  |  |  |  |  |  | Monthly |  |  |  |  |  |  |  |  |  |  |
CC Pharma GmbH [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 454,800
Expense paid |  | $ 454,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 454,800 | 454,800 |  |
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,500 |  | $ 1,500 |  |  |
Common stock shares reserved |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  | 200,000 |  | 200,000 |  |  |
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Preclinical Trials [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock shares reserved |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  | 50,000 |  | 50,000 |  |  |
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | conclusion of Phase I testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock shares reserved |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  | 50,000 |  | 50,000 |  |  |
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase II testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock shares reserved |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  | 50,000 |  |  |  | 50,000 |
Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Conclusion of Phase III testing [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock shares reserved |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |  |  | 50,000 |  | 50,000 |  |  |
Amplerissimo [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 122 |  | $ 124 |  |  |
Frequency of periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Monthly |  | Monthly |  |  |
Operating lease rental expense |  |  |  |  |  |  |  |  |  |  |  |  | $ 399 |  | $ 358 | $ 799 | 715 | $ 1,492 | 1,462 |  |
Operating lease renewal date |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Jul. 31, 2018 |  | Jul. 31, 2018 |  |  |
Decahedron [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  | $ 2,470 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease rental expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,753 | $ 12,076 | $ 27,180 |  |  |
Operating lease expiration date |  |  |  |  |  |  | Oct. 24, 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |
MediHelm S.A. [Member] | SkyPharm [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating lease periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,758 |  |  |  |  |
Frequency of periodic payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Monthly |  |  |  |  |
Operating lease rental expense |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 33,180 |  | $ 24,891 |  | $ 116,400 | 89,323 |  |
Total monthly operating lease amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 8,758 |  |

X
- References No definition available. + Details
Name: | COSM_AdvisoryAgreementTerm
Namespace Prefix: | COSM_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_AmendmentToMaturityDate
Namespace Prefix: | COSM_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_FrequencyOfPeriodicPayment
Namespace Prefix: | COSM_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_LeaseAggrementDescription
Namespace Prefix: | COSM_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_NonrefundableFee
Namespace Prefix: | COSM_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | COSM_OperatingLeasePeriodicPayment
Namespace Prefix: | COSM_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_TermOfOperatingLease
Namespace Prefix: | COSM_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | COSM_TotalMonthlyOperatingLeaseAmount
Namespace Prefix: | COSM_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Describes all significant commitments and obligations resulting from franchise agreements, including a description of the services that the franchisor has agreed to provide for agreements that have not yet been substantially performed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 952 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109207840&loc=SL109207861-203207 + Details
Name: | us-gaap_CommitmentsFromFranchiseAgreements
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total costs of sales and operating expenses for the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_CostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Date which lease or group of leases is set to expire, in CCYY-MM-DD format. + References No definition available. + Details
Name: | us-gaap_LeaseExpirationDate1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717 + Details
Name: | us-gaap_OperatingLeasesRentExpenseNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=COSM_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_SkyPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_AdditionalSpaceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_FirstFloorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_CCPharmaGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_AnastasiosTsekasAndOlgaPartheneaGeorgatwouMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=COSM_IntellectualPropertySaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CreationDateAxis=COSM_OnOctoberOneTwoThousandSixteenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPreclinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseOneTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseTwoTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LeaseArrangementTypeAxis=COSM_ConclusionOfPhaseThreeTestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=COSM_AmplerissimoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=COSM_DecahedronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=COSM_MediHelmSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |